ATTACHMENT C 
ene, Inc. 
1 1075 Roselle Street 
San Diego, CA 92121 
5.0 CONSENT TO PARTICIPATE IN A CLINICAL RESEARCH STUDY 
IMPORTANT : Every person who is invited to consent to experimental medical 
treatment has important rights under the Experimental Subjects' Bill of Rights 
(attached to this consent form) and are protected by California law (Health and 
Safety Code §24172), Be sure to read, understand and ask questions about these 
rights before consenting to participate in this study. Also, please study the patient 
brochure that is provided to further explain the scientific principles and other issues 
in this study. 
STUDY 
A Preliminary Study to Evaluate the Safety and Biologic Effects of an 
Immunotherapeutic [HIV-IT (V)] Based on Gene Transfer in Healthy Subjects Infected 
with HIV- 1. 
PROTOCOL NUMBER: HIV-I-02-1292 
PRINCIPAL INVESTIGATOR: Jeffrey E. Galpin, M.D. 
CO-INVESTIGATOR: Dennis A. Casciato, M.D. 
SPONSORED BY: Viagene, Inc. 
1 1075 Roselle Street 
San Diego, CA 92121 
INTRODUCTION AND PURPOSE 
I, x have been invited 
to participate in this research study ["the Study"]. The purpose of the Study is to evaluate 
the safety and effects on my immune system of a new investigational treatment called HIV- 
IT (V), HIV-ImmunoTherapeutic Vector, [the "Treatment"]. The Treatment is intended for 
healthy individuals infected with the human immunodeficiency virus (HIV-1). 
Recombinant DNA Research, Volume 17 
[915] 
